A. Younes

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.

B. Aggarwal, G. Sethi, K. Ahn, 2007, Blood.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

J. Connors, A. Younes, S. Ansell, 2011 .

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

J. Connors, A. Younes, S. Ansell, 2011 .

Interferon alpha‐2a and 5‐fluorouracil for advanced colorectal carcinoma assessment of activity and toxicity

N. Kemeny, A. Younes, S. Derby, 1990, Cancer.

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

C. Bollard, L. Medeiros, A. Younes, 2011, Experimental hematology.

Estrogen receptor beta is expressed in human colorectal adenocarcinoma.

D. Witte, A. Younes, M. Younes, 2001, Human pathology.

Estrogen receptor beta expression in invasive breast cancer.

R. Laucirica, A. Younes, M. Younes, 2001, Human pathology.

Estrogen receptor β is expressed in human colorectal adenocarcinoma

D. Witte, A. Younes, M. Younes, 2001 .

Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2005, Cancer.

The landscape of new drugs in lymphoma

W. Wilson, R. Advani, J. Vose, 2017, Nature Reviews Clinical Oncology.

Promising Novel Agents for Aggressive B-Cell Lymphoma.

A. Younes, 2016, Hematology/oncology clinics of North America.

Brentuximab Vedotin (SGN-35)

A. Younes, J. Janik, J. Katz, 2011, Clinical Cancer Research.

The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2013, Clinical lymphoma, myeloma & leukemia.

Targeting CD30 in Patients with Hodgkin Lymphoma

S. Pileri, A. Younes, A. Engert, 2020, Hodgkin Lymphoma.

Targeting CD30 in Patients with Hodgkin Lymphoma

S. Pileri, A. Younes, A. Engert, 2015, Hodgkin Lymphoma.

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

E. Shpall, P. Mclaughlin, J. Manning, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune Checkpoint Inhibition in Hodgkin Lymphoma

R. H. Moy, A. Younes, 2018, HemaSphere.

Abstract 3409: MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies

M. Ladanyi, M. Berger, M. Arcila, 2019, Molecular and Cellular Biology / Genetics.

Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.

A. Younes, A. Abu-Alfa, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Serge K. Lyashchenko, S. Larson, L. Norton, 2019, Cancer cell.

FDG PET/CT imaging as a biomarker in lymphoma

A. Younes, A. Gallamini, M. Meignan, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.

C. Pui, B. Coiffier, A. Younes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

B. Coiffier, A. Younes, M. Cairo, 2010, British journal of haematology.

Testicular lymphoma: a mysterious link between the testis and the brain.

Michael L. Wang, A. Younes, 2002, Clinical lymphoma.

Rituximab: review and clinical applications focusing on non-Hodgkin’s lymphoma

A. Younes, K. King, Krista King, 2001, Expert review of anticancer therapy.

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Blood.

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.

P. Mclaughlin, A. Younes, L. Fayad, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens

N. Ueno, F. Cabanillas, A. Younes, 2000 .

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

R. Advani, A. Zelenetz, J. Friedberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HODGKIN LYMPHOMA — FAVORABLE PROGNOSIS STAGE I AND II

R. Advani, Sonali M. Smith, C. Flowers, 2016 .

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.

R. Advani, Sonali M. Smith, C. Flowers, 2016, Oncology.

Treatment of Hodgkin lymphoma

A. Younes, 2016 .

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

A. Zelenetz, J. Friedberg, L. Constine, 2016, Blood.

Hodgkin Lymphoma in Children, Adolescents and Young Adults

D. Friedman, A. Younes, 2012 .

Current treatment strategies in Hodgkin lymphomas

A. Younes, A. Copeland, 2012, Current opinion in oncology.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Maria A. Rodriguez, Y. Oki, Ying Yuan, 2012, Blood.

CD30 in Lymphoma: Its Role in Biology, Diagnostic Testing, and Targeted Therapy

K. Young, A. Younes, E. Sotomayor, 2014 .

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

R. Bociek, J. Leonard, A. Younes, 2008 .

Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy

A. Younes, M. Kadin, 2003 .

Emerging A pplications o f t he T umor N ecrosis F actor F amily o f Ligands a nd R eceptors i n C ancer T herapy

A. Younes, M. Kadin, 2003 .

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

A. Younes, Bharat B Aggarwall, Bharat B. Aggarwall, 2003, Cancer.

CD30/CD30 Ligand and CD40/CD40 Ligand in Malignant Lymphoid Disorders

A. Younes, A. Carbone, 1999, The International journal of biological markers.

Lymphomas and microenvironment: Impact on lymphomagenesis. Foreword.

A. Younes, A. Carbone, 2015, Seminars in cancer biology.

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors

R. Orlowski, G. Georgakis, A. Younes, 2009, British journal of haematology.

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

A. Younes, L. Fayad, B. Pro, 2006, Blood.

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next‐generation sequencing approach

Maria A. Rodriguez, Y. Oki, V. Carlton, 2015, British journal of haematology.

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

P. Zinzani, P. Zinzani, A. Younes, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Scott E. Smith, J. Connors, A. Younes, 2010 .

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2008, Cancer.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

A. Zelenetz, S. Horwitz, A. Younes, 2019, Blood.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

John P Leonard, J. Leonard, A. Younes, 2010, The New England journal of medicine.

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

A. Younes, A. Alperovich, 2016, Cancer journal.

Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer.

A. Younes, 2016, Journal of oncology practice.

Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

S. Ansell, A. Younes, 2016, Seminars in hematology.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

A. Zelenetz, N. Shukla, M. Perales, 2015, The Lancet. Oncology.

Role of CD30 Targeting in Malignant Lymphoma

A. Younes, Anita Kumar, 2014, Current Treatment Options in Oncology.

Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.

A. Younes, 2014, Hematology/oncology clinics of North America.

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

A. Younes, S. Harrison, R. Bugarini, 2014, Leukemia & lymphoma.

Anaplastic Large Cell Lymphoma

J. Delabie, P. Zinzani, S. Rodig, 2014 .

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

L. Gordon, A. Younes, L. Kwak, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody-drug conjugate technology development for hematologic disorders.

M. Czuczman, N. Bander, A. Younes, 2012, Clinical advances in hematology & oncology : H&O.

CD30-targeted antibody therapy

A. Younes, 2011, Current opinion in oncology.

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

J. Connors, K. Savage, Y. Oki, 2021, Haematologica.

Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

R. Advani, J. Connors, K. Savage, 2019, Blood.

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

J. Connors, L. Specht, P. Zinzani, 2020, Leukemia & lymphoma.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

K. Savage, D. Neuberg, G. Pinkus, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 safety and dose escalation of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K in relapsed or refractory lymphoma and multiple myeloma

I. Flinn, Y. Oki, A. Younes, 2017 .

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Scott E. Smith, J. Connors, K. Savage, 2016, Blood.

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting

J. Connors, A. Younes, A. Engert, 2016, Clinical trials.

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Michael L. Wang, Y. Oki, A. Younes, 2014, British journal of haematology.

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, British journal of haematology.

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Y. Oki, Jiexin Zhang, Shouhao Zhou, 2013, Clinical Cancer Research.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2013, British journal of haematology.

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

J. Connors, S. Ansell, A. Younes, 2013, The Lancet. Oncology.

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T‐cell lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2013, British journal of haematology.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J. Shah, J. Wood, P. Mclaughlin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimising the lymphoma response criteria in the era of targeted therapy.

A. Hagenbeek, B. Coiffier, A. Younes, 2011, The Lancet. Oncology.

Hodgkin Lymphoma : Advancing Beyond Standard Management

V. Diehl, B. Cheson, J. Radford, 2009 .

Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma

A. Younes, M. Fanale, 2012, Drugs.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.

G. Georgakis, A. Younes, 2005, Future oncology.

Heat shock protein-based cancer vaccines

Y. Oki, A. Younes, 2004, Expert review of vaccines.

Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal–Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death

L. Medeiros, G. Georgakis, A. Younes, 2006, Clinical Cancer Research.

Revival of PI3K inhibitors in non-Hodgkin's lymphoma.

A. Younes, C. Batlevi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphocyte-Predominant Hodgkin Lymphoma

A. Younes, A. Engert, 2011 .

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus high‐dose cyclosphosphamide with G‐CSF support in patients with relapsed and refractory aggressive non‐Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 1998, British journal of haematology.

Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations.

M. Andreeff, F. Cabanillas, A. Younes, 1997, Leukemia & lymphoma.

Targeting lymphoma cells and their microenvironment with novel antibodies.

A. Younes, A. Wedgwood, 2006, Clinical lymphoma & myeloma.

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results

E. Shpall, A. Younes, Y. Nieto, 2012, Leukemia & lymphoma.

Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus.

A. Younes, M. Younes, M. Schwartz, 1999, Human pathology.

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2010, British journal of haematology.

Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Investigational New Drugs.

Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.

J. Cox, F. Cabanillas, A. Younes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Highlights in lymphoma from the 2011 American Society of Hematology (ASH) Annual Meeting.

A. Younes, 2012, Clinical advances in hematology & oncology : H&O.

Gallium Scan after the Second and Fourth Chemotherapy Cycle is Predictive in Aggressive Non-Hodgkin ’ s Lymphomas

Maria A. Rodriguez, D. Podoloff, P. Mclaughlin, 2012 .

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Leukemia & lymphoma.

CD30 ligand in lymphoma patients with CD30+ tumors.

K. Kliche, M. Andreeff, F. Cabanillas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman.

F. Cabanillas, A. Younes, J. Seymour, 1994, Leukemia & lymphoma.

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Y. Oki, L. Medeiros, A. Younes, 2016, Leukemia & lymphoma.

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor

G. Garcia-Manero, Y. Boumber, A. Younes, 2011, Expert opinion on investigational drugs.

Novel small-molecule therapy of Hodgkin lymphoma

G. Georgakis, A. Younes, D. Buglio, 2007, Expert review of anticancer therapy.

Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience

A. Zelenetz, A. Younes, P. Hamlin, 2021, Leukemia & lymphoma.

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.

A. Zelenetz, M. Perales, S. Devlin, 2020, Blood advances.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

A. López-Guillermo, F. Bosch, A. Nagler, 2019, The Lancet. Haematology.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, M. Perales, M. Fleisher, 2017, Blood.

Current and emerging new treatment strategies for mantle cell lymphoma

A. Younes, K. Humala, 2013, Leukemia & lymphoma.

TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA

A. Zelenetz, A. Younes, A. Alperovich, 2017, Leukemia & lymphoma.

Histone deacetylase inhibitors in the treatment of lymphoma.

A. Younes, M. Lemoine, 2010, Discovery medicine.

Retinoic acid stimulates the protein kinase C pathway before activation of its beta-nuclear receptor during human teratocarcinoma differentiation.

E. Dmitrovsky, W. Miller, J. Kurie, 1993, Biochimica et biophysica acta.

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death

M. Andreeff, S. O'brien, G. Georgakis, 2005, British journal of haematology.

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

Michael R. Green, A. Mottok, J. Baselga, 2019, bioRxiv.

Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies

M. Andreeff, F. Cabanillas, A. Younes, 1997, British journal of haematology.

CD40 ligand (CD154) and tumour necrosis factor‐related apoptosis inducing ligand (Apo‐2L) in haematological malignancies

A. Younes, P. Fiumara, 2001, British journal of haematology.

TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2

T. McDonnell, R. Meyn, A. Younes, 2001, Oncogene.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

R. Advani, J. Connors, K. Savage, 2021, The Lancet. Haematology.

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Scott E. Smith, Eric Lester, Theodore Karrison, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.

L. Medeiros, G. Georgakis, A. Younes, 2006, Experimental hematology.

Reply to M. Skelin et al.

L. Staudt, A. Younes, W. H. Wilson, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

T. Pan, Y. Oki, A. Younes, 2014, British journal of haematology.

PET-Based Staging Reduces the Prognostic Impact of Early Disease Progression in Patients with Follicular Lymphoma

V. Seshan, A. Zelenetz, M. Federico, 2019, SSRN Electronic Journal.

Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

P. Mclaughlin, A. Younes, L. Kwak, 2019, British journal of haematology.

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low‐grade B‐cell lymphomas

P. Mclaughlin, A. Younes, L. Kwak, 2015, British journal of haematology.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

K. Savage, M. Shipp, A. Santoro, 2016 .

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.

J. Connors, A. Younes, S. Ansell, 2017, Blood.

Nodular lymphocyte predominant Hodgkin's lymphoma.

A. Younes, M. Fanale, 2008, Cancer treatment and research.

LYMPHOID NEOPLASIA Integrated genomic DNA/RNA pro ﬁ ling of hematologic malignancies in the clinical setting

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016 .

Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia.

A. Younes, M. Younes, M. Chirala, 2003, European journal of cancer.

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

B. Aggarwal, A. Gillenwater, F. Cabanillas, 2001, Blood.

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

P. Mclaughlin, J. Manning, L. Medeiros, 2003, Cancer.

The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism

A. Younes, D. Buglio, V. Mamidipudi, 2010, British journal of haematology.

Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

L. Medeiros, A. Younes, Lianchun Xiao, 2012, Journal of Hematology & Oncology.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Michael L. Wang, Y. Oki, H. Kantarjian, 2018, Cancer.

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

B. Andersson, L. Medeiros, A. Younes, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.

Y. Oki, A. Younes, L. Fayad, 2012, Blood.

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

P. Mclaughlin, F. Cabanillas, M. Overman, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

L. Gordon, M. Czuczman, J. Friedberg, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

Michael L. Wang, A. Younes, L. Fayad, 2006, European journal of cancer.

Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality.

A. Younes, D. Kontoyiannis, J. Tarrand, 2006, Clinical lymphoma & myeloma.

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.

J. Vose, L. Gordon, M. Czuczman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.

Maria A. Rodriguez, S. Tucker, P. Mclaughlin, 2003, International journal of radiation oncology, biology, physics.

Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma.

A. Younes, B. Leigh, K. Hariharan, 2003, Clinical lymphoma.

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.

G. Georgakis, A. Younes, D. Buglio, 2008, Blood.

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

Y. Oki, E. Shpall, A. Younes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.

I. Flinn, Y. Oki, S. Horwitz, 2013 .

Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2006, Leukemia & lymphoma.

A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results.

M. Andreeff, P. Mclaughlin, F. Cabanillas, 1996, Blood.

Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.

N. Kemeny, A. Younes, 1992, Seminars in oncology.

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

A. Younes, Nousheen Samad, 2010, OncoTargets and therapy.

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate end points in lymphoma.

A. Younes, C. Batlevi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel therapy for Hodgkin lymphoma.

A. Younes, C. Batlevi, 2013, Hematology. American Society of Hematology. Education Program.

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.

A. Younes, D. Buglio, H. Martinez-Valdez, 2011, Blood.

Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors

B. Aggarwal, D. McConkey, G. Georgakis, 2004, Clinical Cancer Research.

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, S. Horwitz, A. Younes, 2013, Clinical advances in hematology & oncology : H&O.

oligonucleotide in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018 .

The heat shock protein 90 inhibitor 17‐AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9

G. Georgakis, A. Younes, Yang Li, 2006, British journal of haematology.

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

M. Kaminski, J. Connors, I. Flinn, 2018, Blood.

Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.

J. Connors, L. Specht, P. Zinzani, 2018 .

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E Smith, Bruce D Cheson, Andreas Engert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current role of gemcitabine in the treatment of Hodgkin lymphoma

Y. Oki, A. Younes, 2008, Leukemia & lymphoma.

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma.

F. Cabanillas, A. Younes, M. Rodriguez, 1995, Leukemia & lymphoma.

Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

C. Grommes, A. Younes, 2017, Cancer cell.

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 2012, Leukemia & lymphoma.

Experience with 9-Cis Retinoic Acid in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma

P. Mclaughlin, F. Cabanillas, M. Cristofanilli, 2000, Leukemia & lymphoma.

Unbalanced expression of Fas and CD40 in mantle cell lymphoma

S. Zhao, M. Andreeff, F. Cabanillas, 1998, British journal of haematology.

Analysis of p53 gene deletions in patients with non‐Hodgkin's lymphoma by dual‐colour fluorescence in‐situ hybridization

M. Andreeff, F. Cabanillas, A. Younes, 1997, British journal of haematology.

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

G. Salles, A. Zelenetz, A. Younes, 2020 .

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease

M. Andreeff, F. Cabanillas, A. Younes, 2002, Cancer.

Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers.

F. Cabanillas, A. Younes, P. Fiumara, 2001, Blood.

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, P. Mclaughlin, 2004 .

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

L. Gordon, A. Younes, L. Kwak, 2009 .

Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

D. Podoloff, T. Manshouri, P. Mclaughlin, 2009 .

Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.

J. Leonard, A. Younes, N. Bartlett, 2008 .

Decreased sensitivity of 17p‐deleted chronic lymphocytic leukemia cells to a small molecule BCL‐2 antagonist ABT‐737

M. Andreeff, K. Kojima, V. Ruvolo, 2012, Cancer.

In the spotlight: a novel CD37 antibody-drug conjugate.

A. Younes, M. Palomba, 2013, Blood.

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

R. Advani, J. Connors, J. Radford, 2018, Blood.

Functional expression of TRAIL by lymphoid and myeloid tumour cells

S. Zhao, M. Andreeff, Yan Wang, 1999, British journal of haematology.

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue

T. Willis, M. Faham, K. Kong, 2021, Clinical lymphoma, myeloma & leukemia.

Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: Clues but no clear answers

A. Younes, 2008, Autophagy.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

W. Wilson, Y. Oki, F. Turturro, 2018, Haematologica.

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

J. Connors, K. Savage, Y. Oki, 2018, Blood.

Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

P. Mclaughlin, L. Medeiros, A. Younes, 2005 .

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

V. Diehl, A. Younes, L. Miller, 2012, Blood.

Precision medicine in diffuse large B-cell lymphoma: hitting the target

M. Kersten, J. Radford, M. Federico, 2015, Haematologica.

Phase II study of idelalisib, a selective inhibitor of PI3K d , for relapsed/refractory classical Hodgkin lymphoma

A. Younes, M. Fanale, C. Moskowitz, 2017 .

CD30 ligand is expressed on resting normal and malignant human B lymphocytes

M. Andreeff, F. Cabanillas, A. Younes, 1996, British journal of haematology.

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Scott E. Smith, J. Connors, K. Savage, 2013 .

Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.

D. Beer, G. Georgakis, A. Younes, 2006, European journal of cancer.

Fas ligand expression in esophageal carcinomas and their lymph node metastases

A. Younes, M. Younes, M. Schwartz, 2000, Cancer.

CD 30-ligand and CD 40-ligand expression in lymph nodes involved with Hodgkin ' s disease

S. Zhao, K. Kliche, M. Andreeff, 2005 .

CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease.

S. Zhao, K. Kliche, M. Andreeff, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

I. Flinn, Y. Oki, A. Younes, 2016, The Lancet. Oncology.

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

R. Bociek, G. Salles, G. Martinelli, 2014 .

A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.

A. Younes, R. Martell, M. Crump, 2013 .

Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.

L. North, A. Younes, F. Hagemeister, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

J. Vose, A. Zelenetz, M. Czuczman, 2010, British Journal of Cancer.

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma

J. Burke, S. Ferrari, A. Younes, 2022, Blood advances.

Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma.

A. Younes, Yuan Ji, L. Fayad, 2007 .

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Marilyn M. Li, Somak Roy, Marina N Nikiforova, 2017, The Journal of molecular diagnostics : JMD.

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

D. Berry, S. Faria, L. Medeiros, 2011 .

Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.

D. Ramies, A. Younes, K. Blum, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3.

F. Cabanillas, A. Younes, A. Sarris, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

The Histone Deacetylase Inhibitor Vorinostat (SAHA) Induces Apoptosis and Cell Cycle Arrest in Hodgkin Lymphoma (HL) Cell Lines by Altering Several Survival Signaling Pathways and Synergizes with Doxorubicin, Gemcitabine and Bortezomib.

G. Georgakis, A. Younes, Yang Li, 2006 .

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Yuan Ji, Paolo Anderlini, A. Younes, 2011, British journal of haematology.

Cytomegalovirus pneumonia in patients with lymphoma

A. Younes, J. Tarrand, H. Torres, 2005, Cancer.

Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial

R. Kurzrock, P. Mclaughlin, L. North, 1997, British journal of haematology.

Pulmonary changes in patients with lymphoma who receive paclitaxel.

L. North, F. Cabanillas, A. Younes, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 2006, Leukemia & lymphoma.

Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design

A. Zelenetz, A. Younes, E. Drill, 2022, Leukemia & lymphoma.

The mTOR inhibitor CCI-779 (temsirolimus) downregulates p21 and induces cell cycle arrest and autophagy in mantle cell lymphoma (MCL).

G. Georgakis, A. Younes, Y. Li, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis

G. Rassidakis, L. Medeiros, G. Georgakis, 2004, Modern Pathology.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

P. Richardson, Y. Oki, H. Ovaa, 2011, Current cancer drug targets.

Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease.

Kong-Chao Chang, L. Abruzzo, A. Younes, 2003, Human pathology.

Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease.

F. Cabanillas, A. Younes, J. Ayoub, 1999, Leukemia & lymphoma.

From empiric to mechanism-based therapy for peripheral T cell lymphoma

A. Intlekofer, A. Younes, 2014, International Journal of Hematology.

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

S. Tomany, F. Cabanillas, A. Younes, 2001, Bone Marrow Transplantation.

Novel immunotherapies in lymphoid malignancies

A. Younes, R. Brentjens, C. Batlevi, 2016, Nature Reviews Clinical Oncology.

Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

I. Flinn, P. Mclaughlin, F. Cabanillas, 2004, Clinical Cancer Research.

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

V. Seshan, E. de Stanchina, G. Nanjangud, 2018, Proceedings of the National Academy of Sciences.

Targeted Therapy in Lymphoma

A. Younes, A. Wedgwood, 2008 .

Novel treatment strategies for aggressive non-Hodgkin’s lymphoma

A. Younes, L. Fayad, 2006, Expert opinion on pharmacotherapy.

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Sang Hoon Lee, Wen-Kai Weng, Mohammad Luqman, 2008, Blood.

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

J. Vose, J. Friedberg, B. Cheson, 2013, Leukemia & lymphoma.

Novel therapeutic agents for relapsed classical Hodgkin lymphoma

A. Younes, Gottfried von Keudell, 2018, British journal of haematology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

A. Younes, S. Vardhana, 2016, Haematologica.

Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma

A. Younes, E. Matsuki, 2016, Current Treatment Options in Oncology.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OncoTree: A Cancer Classification System for Precision Oncology.

Benjamin E. Gross, Stuart M. Gardos, N. Schultz, 2021, JCO clinical cancer informatics.

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

I. Flinn, Y. Oki, A. Younes, 2017, Haematologica.

Apoptosis. Molecules and mechanisms.

M. Konopleva, Z. Estrov, S. Zhao, 1999, Advances in experimental medicine and biology.

Precision therapy for lymphoma—current state and future directions

A. Intlekofer, A. Younes, Anas Younes, 2014, Nature Reviews Clinical Oncology.

Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus.

A. Younes, M. Younes, J. Lechago, 2000, Human pathology.

Reed-Sternberg cells and the TNF family of receptors/ligands.

A. Younes, K. Clodi, Anas Younes, 1997, Leukemia & lymphoma.

Epigenetics of T‐cell Lymphoma

S. Whittaker, A. Younes, O. O’Connor, 2021 .

Follicular lymphoma

A. López-Guillermo, J. Fitzgibbon, A. Younes, 2019, Nature Reviews Disease Primers.

Emerging epigenetic-modulating therapies in lymphoma

L. Pasqualucci, A. Melnick, A. Younes, 2019, Nature Reviews Clinical Oncology.

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy

A. Younes, Y. Kwong, A. Carbone, 2014, Annals of Hematology.

Targeting oncogenic and epigenetic survival pathways in lymphoma

A. Younes, L. Leslie, 2013, Leukemia & lymphoma.

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

V. Seshan, G. Salles, A. Zelenetz, 2021, Clinical Cancer Research.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

L. Staudt, W. Wilson, L. Sehn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

D. Potvin, A. Younes, M. Crump, 2017, British journal of haematology.

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma

V. Seshan, D. Scheinberg, J. Philip, 2016, Oncotarget.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

Michael L. Wang, J. Shah, M. Wang, 2013, Leukemia.

Expression of heat-shock protein-90 in non-Hodgkin's lymphomas

G. Rassidakis, L. Medeiros, G. Georgakis, 2005, Modern Pathology.

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.

Mamoun Younes, Georgios Georgakis, Jean Nicolas Vauthey, 2003, Blood.

Expression of Tumour Necrosis Factor (TNF)-related Apoptosis-Inducing Ligand (TRAIL) Receptors and Sensitivity to TRAIL-induced Apoptosis in Primary B-cell Acute Lymphoblastic Leukaemia Cells

U. Jaeger, A. Younes, H. Gadner, 2000 .

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

V. Seshan, J. Philip, E. de Stanchina, 2018, Cell reports.

Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): International expert panel analysis

C. Pui, B. Coiffier, B. Cheson, 2007 .

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016, Blood.

Hodgkin Lymphoma: A Comprehensive Overview

A. Younes, A. Engert, 2020 .

Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.

M. Konopleva, M. Andreeff, S. Kornblau, 2004, Molecular cancer therapeutics.

Clinical Trials in the Genomic Era.

A. Iasonos, A. Younes, E. Joffe, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytokines and lymphomas.

G. Georgakis, A. Younes, 2005, Cancer treatment and research.

Expression of tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) receptors and sensitivity to TRAIL‐induced apoptosis in primary B‐cell acute lymphoblastic leukaemia cells

U. Jaeger, A. Younes, H. Gadner, 2000, British journal of haematology.

Emerging drugs for diffuse large B-cell lymphoma

A. Younes, P. Mondello, 2015, Expert review of anticancer therapy.

World Health Organization classification

A. Younes, A. Dogan, 2016 .

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphomas The Clinical Significance of Molecular Response in Indolent Follicular

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2013 .

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

J. Connors, J. Friedberg, J. Leonard, 2017, Journal of the National Cancer Institute.

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

R. Bociek, F. Hernandez-Ilizaliturri, A. Younes, 2016, Haematologica.

Hodgkin lymphoma microenvironment: old and new therapeutic targets

A. Younes, C. Batlevi, 2015 .

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

S. Horning, T. Illidge, A. Younes, 2013, Leukemia & lymphoma.

Novel targeted therapies in diffuse large B-cell lymphoma.

A. Younes, N. Mehta-Shah, 2015, Seminars in hematology.

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.

A. Younes, M. Kadin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACR Appropriateness Criteria: Localized nodal indolent lymphoma.

R. Advani, C. Flowers, L. Constine, 2013, Oncology.

LOCALIZED NODAL INDOLENT LYMPHOMA

R. Advani, C. Flowers, L. Constine, 2013 .

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

J. Connors, K. Savage, Y. Oki, 2017, The New England journal of medicine.

Tumor Targeted Nanoparticles Improve Therapeutic Index of BCL2 and MCL1 dual inhibition.

V. Seshan, K. Manova-Todorova, D. Heller, 2020, Blood.

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma

J. Armitage, Lynette M. Smith, P. Bierman, 2018, British journal of haematology.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018, Journal of Immunotherapy for Cancer.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

V. Seshan, A. Zelenetz, E. Papaemmanuil, 2018, Blood Cancer Journal.

Histone deacetylase inhibitors in lymphoma

A. Younes, D. Buglio, A. Copeland, 2010, Current opinion in oncology.

Beyond chemotherapy: new agents for targeted treatment of lymphoma

A. Younes, 2011, Nature Reviews Clinical Oncology.

graft-versus-host disease, and treatment-related mortality immunotherapy for indolent lymphoma: low incidence of toxicity, acute Nonablative allogeneic hematopoietic transplantation as adoptive

P. Mclaughlin, F. Cabanillas, A. Younes, 2013 .

lymphoma alternating triple therapy (ATT) regimen in patients with stage IV indolent Fludarabine, mitoxantrone, dexamethasone (FND) compared with an

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2013 .

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

R. Advani, L. Gordon, J. Connors, 2019, Clinical Cancer Research.

ACR appropriateness criteria follow-up of Hodgkin lymphoma.

R. Advani, Sonali M. Smith, C. Flowers, 2014, Journal of the American College of Radiology : JACR.

Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4

U. Gerdemann, C. Cruz, H. Heslop, 2011 .

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

U. Gerdemann, C. Cruz, H. Heslop, 2011, Clinical Cancer Research.

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

J. Leonard, A. Younes, N. Bartlett, 2009, British journal of haematology.

Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.

S. Tucker, J. Cox, F. Cabanillas, 2003, International journal of radiation oncology, biology, physics.

Novel Agents Targeting Oncogenic Pathways in Lymphoma

A. Younes, 2013 .

Selective agnostic monoclonal antibodies to the TRAIL receptors R1 and R2 induce cell death and potentiate the effect of chemotherapy and bortezomib in primary and cultured lymphoma cells.

M. Andreeff, G. Georgakis, A. Younes, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Scott E. Smith, J. Connors, K. Savage, 2015, Blood.

Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial

Jeffrey E. Lee, R. Winn, Yu Shen, 1999, Annals of Internal Medicine.

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

A. Younes, E. Derenzini, Anas Younes, 2011, Genome Medicine.

Hodgkin lymphoma: epidemiology, histopathology, staging, and treatment

A. Younes, E. Derenzini, 2011 .

Coexpression of CD40 and CD40 ligand in B‐cell lymphoma cells

K. Kliche, M. Andreeff, F. Cabanillas, 1998, British journal of haematology.

K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis.

A. Younes, H. Maeng, L. Fayad, 2007, Blood.

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

V. Seshan, A. Zelenetz, S. Horwitz, 2021, Blood Cancer Journal.

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

A. Zelenetz, A. Toure, S. Horwitz, 2019, Blood Cancer Journal.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

P. Mclaughlin, F. Cabanillas, K. Young, 2012, The Lancet. Oncology.

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees.

A. Younes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

V. Seshan, A. Zelenetz, M. Federico, 2020, European journal of cancer.

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

G. Ayers, S. Verstovsek, P. Mclaughlin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

V. Seshan, E. de Stanchina, A. Younes, 2021, Cell Reports Medicine.

Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.

Y. Oki, A. Younes, S. Chaturvedi, 2020, Cancer treatment and research communications.

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood advances.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

J. Friedberg, I. Flinn, Y. Oki, 2014, The Lancet. Oncology.

Hodgkin's lymphoma: molecular targets and novel treatment strategies.

G. Georgakis, A. Younes, V. Yazbeck, 2006, Future oncology.

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

A. Younes, B. Hodkinson, J. Brody, 2020, Translational oncology.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

V. Seshan, J. Baselga, D. Scheinberg, 2017, JCI insight.

High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

A. Younes, A. Rosenthal, 2017, Blood reviews.

Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood.

The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma

A. Zelenetz, A. Younes, A. Alperovich, 2022, Leukemia & lymphoma.

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood Cancer Journal.

Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.

A. Younes, K. King, 2000, Seminars in oncology.

Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Leukemia & lymphoma.

Hodgkin disease risk: Role of genetic polymorphisms and gene–gene interactions in inflammation pathway genes

S. Strom, A. Younes, C. Etzel, 2011, Molecular carcinogenesis.

ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma

R. Advani, Sonali M. Smith, C. Flowers, 2015, American journal of clinical oncology.

Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma

A. Younes, M. Brenner, Satoshi Takahashi, 2001, Cancer Gene Therapy.

Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.

Michael R. Green, V. Seshan, Phani Ghanakota, 2019, JCI insight.

Cancer Therapy : Preclinical See commentary by Rezvani , p . 6955 Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A 4

U. Gerdemann, C. Cruz, H. Heslop, 2011 .

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

E. de Stanchina, A. Younes, Man Jiang, 2023, Nature Communications.

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

C. Leslie, V. Seshan, A. Melnick, 2021, Nature Communications.

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

A. Iasonos, A. Stathis, A. Younes, 2018, Clinical Cancer Research.

Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.

J. Vose, A. Zelenetz, J. Leonard, 2008, Clinical advances in hematology & oncology : H&O.

Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphoma

A. LaCasce, D. Neuberg, Y. Oki, 2013, British journal of haematology.

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

R. Bociek, G. Salles, G. Martinelli, 2017, Haematologica.

Essential role of TAK1 in regulating mantle cell lymphoma survival.

A. Younes, Kate F. Byth, D. Buglio, 2012, Blood.

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Nancy Whiting, R. Advani, A. Younes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma

I. Flinn, M. Maris, R. Sims, 2018 .

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.

S. Horning, M. Goris, D. Podoloff, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

R. Bociek, J. Paulus, Y. Oki, 2011, The Lancet. Oncology.

Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study

P. Mclaughlin, A. Younes, B. Dabaja, 2012, Leukemia & lymphoma.

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, A. Younes, 2005, Bone Marrow Transplantation.

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma

A. Zelenetz, A. Younes, E. Drill, 2019, Haematologica.

Experience with heat shock protein‐peptide complex 96 vaccine therapy in patients with indolent non‐Hodgkin lymphoma

Y. Oki, P. Srivastava, P. Mclaughlin, 2007, Cancer.

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

I. Flinn, M. Maris, R. Sims, 2015 .

A Phase II Study of Heat Shock Protein–PeptideComplex–96 Vaccine Therapy in Patients with Indolent Non-Hodgkin's Lymphoma

A. Younes, 2003 .

Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia

M. Andreeff, A. Younes, U. Consoli, 1998, British journal of haematology.

A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

A. Younes, K. Blum, P. Foster, 2015, British journal of haematology.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience

M. Munsell, N. Ueno, B. Andersson, 2008, Haematologica.

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

R. Advani, A. Younes, J. Drachman, 2006 .

Impact of high-dose chemotherapy on peripheral T-cell lymphomas.

M. Munsell, F. Cabanillas, B. Andersson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of mTOR inhibition in hematologic malignancies.

A. Younes, Nousheen Samad, 2011, The oncologist.

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2017, Blood.

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

P. Mclaughlin, F. Cabanillas, A. Younes, 1994, Investigational New Drugs.

Clinicopathologic and Molecular Features of Hodgkin Lymphoma

A. Younes, A. Carbone, 2003, Cancer biology & therapy.

Which therapies for which patients

A. Younes, M. Karuturi, 2013 .

Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Scott E. Smith, J. Connors, K. Savage, 2015, Clinical advances in hematology & oncology : H&O.

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Scott E. Smith, J. Friedberg, A. Younes, 2014, Leukemia & lymphoma.

ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.

R. Advani, Sonali M. Smith, C. Flowers, 2016, American journal of clinical oncology.

Early-stage hodgkin's lymphoma: in pursuit of perfection.

A. Younes, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

A. Zelenetz, M. Voss, A. Chen, 2017, Clinical Cancer Research.

Impact o f H igh-Dose C hemotherapy o n P eripheral T -Cell Lymphomas

M. Munsell, F. Cabanillas, B. Andersson, 2001 .

Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30

J. Leonard, A. Younes, N. Bartlett, 2005 .

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

A. Zelenetz, H. Schoder, S. Devlin, 2018, Blood.

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

P. Mclaughlin, A. Younes, L. Kwak, 2008 .

Paclitaxel (Taxol) for the treatment of lymphoma.

L. North, F. Cabanillas, A. Younes, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

A. Zelenetz, Laura H. Tang, S. Horwitz, 2016 .

Lymphomagenesis in Hodgkin lymphoma.

A. Younes, E. Matsuki, 2015, Seminars in cancer biology.

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

J. Cox, F. Cabanillas, A. Younes, 2002 .

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

V. Seshan, G. Salles, A. Zelenetz, 2022, Blood Cancer Journal.

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Radiotherapy Alone for Lymphocyte‐Predominant Hodgkin's Disease

J. Cox, F. Cabanillas, A. Younes, 2002, Cancer journal.

Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy

A. Younes, Á. Illés, Á. Jóna, 2012 .

Novel Therapy of Relapsed and Refractory Classical Hodgkin’s Lymphoma

A. Younes, E. Derenzini, D. Buglio, 2011 .

CD30 in Lymphoma: Its Role in Biology, Diagnostic Testing, and Targeted Therapy

K. Young, A. Younes, E. Sotomayor, 2014 .

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

P. Mclaughlin, A. Younes, L. Fayad, 2005 .

New molecular targets for treatment of lymphoma

A. Younes, B. Pro, 2004, Current oncology reports.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma?

Y. Oki, A. Younes, 2010, Current hematologic malignancy reports.

Hodgkin lymphoma risk: Role of genetic polymorphisms and gene–gene interactions in DNA repair pathways

S. Strom, A. Younes, C. Etzel, 2011, Molecular carcinogenesis.

From drug discovery to biomarker-driven clinical trials in lymphoma

D. Berry, A. Younes, 2012, Nature Reviews Clinical Oncology.

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab

A. Zelenetz, J. Teruya-Feldstein, A. Younes, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma

A. Younes, M. Bennett, K. Orford, 2015 .

Clinical applications of genome studies

A. Younes, 2017, Hematological oncology.

Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform

A. Zelenetz, P. Stephens, R. Yelensky, 2013 .

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

V. Seshan, Sonali M. Smith, A. Zelenetz, 2020 .

Defining Progression Free Survival After Multiple Lines of Therapy and Impact of Dynamic Changes in FLIPI for Multiply Relapsed Follicular Lymphoma in the Rituximab Era Treated at Memorial Sloan Kettering Cancer Center (MSKCC)

V. Seshan, A. Zelenetz, S. Horwitz, 2017 .

A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma

I. Flinn, Y. Oki, A. Fattaey, 2013 .

Diffuse large B-cell lymphoma: changing treatment paradigms.

A. Younes, C. Batlevi, 2014, Oncology.

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.

P. Mclaughlin, A. Younes, M. Fanale, 2010 .

The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma

P. Zinzani, A. Younes, M. Lemoine, 2011 .

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

D. Berry, L. Doyle, A. Younes, 2011 .

PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

M. Sadelain, A. Younes, R. Furman, 2019, Hematological Oncology.

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.

A. Zelenetz, S. Horwitz, A. Younes, 2021, Blood advances.

New treatment strategies for aggressive lymphoma.

A. Younes, 2004, Seminars in oncology.

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2014, British journal of haematology.

Vorinostat (SAHA) Inhibits STAT6 Phosphorylation and Transcription, Downregulates Bcl-xL, and Induces Apoptosis in Hodgkin Lymphoma (HL) Cell Lines.

G. Georgakis, A. Younes, D. Buglio, 2007 .

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

P. Mclaughlin, A. Younes, R. Martell, 2007 .

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

R. Bociek, P. Mclaughlin, A. Younes, 2007 .

Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy, and Synergy with Vorinostat (SAHA).

S. Kondo, G. Georgakis, A. Younes, 2006 .

Clinical development of panobinostat in classical Hodgkin’s lymphoma

Y. Oki, A. Younes, A. Copeland, 2011, Expert review of hematology.

Phase II Study of Mocetinostat ( MGCD 0103 ) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

R. Bociek, J. Paulus, Y. Oki, 2016 .

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

A. Younes, Á. Jóna, 2010, Blood reviews.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

R. Advani, A. Younes, N. Bartlett, 2012, The oncologist.

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

A. Younes, E. Derenzini, 2013, Expert opinion on investigational drugs.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

V. Seshan, J. Baselga, D. Scheinberg, 2017, JCI insight.

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

J. Vose, M. Czuczman, A. Younes, 2004 .

Using social media in oncology for education and patient engagement.

Robert S. Miller, A. Younes, M. Thompson, 2012, Oncology.

Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma.

S. Zhao, M. Andreeff, F. Cabanillas, 1995, Blood.

Inhibition of the phosphatidylinositol‐3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma

G. Mills, G. Georgakis, A. Younes, 2005, British journal of haematology.

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

Andreas Engert, Arnold S. Freedman, Martin J. S. Dyer, 2014, British journal of haematology.

K 1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis

A. Younes, H. Maeng, L. Fayad, 2007 .

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

R. Bociek, R. Gascoyne, L. Gordon, 2012 .

Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors

R. Kurzrock, A. Naing, D. Hong, 2008 .

First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052.

R. Kurzrock, D. Hong, A. Younes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New drugs for new targets in lymphoma

A. Younes, 2019, Hematological oncology.

A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma

Vivek Subbiah, Mary F. McGuire, Robert E. Brown, 2013, Oncotarget.

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

I. Lossos, J. Burke, B. Cheson, 2022, Blood advances.

ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study.

Michael L. Wang, A. Younes, L. Fayad, 2005 .

Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.

A. Younes, A. Wedgwood, 2007, Clinical lymphoma & myeloma.

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).

J. Friedberg, I. Flinn, Y. Oki, 2013 .

Antibody-drug conjugates in hematologic malignancies.

A. Younes, L. Leslie, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

L. Staudt, W. Wilson, L. Sehn, 2019, Blood.

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

R. Bociek, A. Younes, Y. Kasamon, 2011 .

Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1997, Leukemia & lymphoma.

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting

A. Zelenetz, P. Goyal, S. Horwitz, 2023, Cancers.

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

A. López-Guillermo, A. Nagler, B. K. Masouleh, 2017 .

Erratum: The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma (Blood Cancer Journal (2011) 1 (e46) DOI:10.1038/bcj.2011.46)

H. Katayama, S. Sen, A. Younes, 2014 .

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

A. Zelenetz, A. Toure, S. Horwitz, 2019, Blood Cancer Journal.

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

H. Tun, A. Younes, M. Lunning, 2020 .

Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma

B. Leber, P. Mclaughlin, A. Younes, 2008, British journal of haematology.

Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

L. Gordon, M. Czuczman, J. Friedberg, 2005 .

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

R. Bociek, J. Leonard, B. Cheson, 2004 .

Handbook of Lymphoma.

A. Younes, 2017, Anticancer research.

The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

D. Berry, L. Medeiros, A. Younes, 2010 .

Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant

J. Kaufman, A. Younes, A. Engert, 2010 .

c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma.

G. Rassidakis, L. Medeiros, G. Georgakis, 2003, Blood.

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

L. Sehn, C. Ward, A. Younes, 2019, Blood.

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2004 .

A Pilot Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma (HL): Delivering Cross Fire Radiation by Targeting Reactive B Cells in the Microenvironment.

P. Mclaughlin, A. Younes, F. Wong, 2005 .

MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma

Juan F. García, A. M. Martín-Moreno, M. Piris, 2013, British journal of haematology.

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

G. Fingerle-Rowson, S. Ferrari, A. Younes, 2017 .

RECURRENT HODGKIN LYMPHOMA Expert Panel on Radiation Oncology

Leslie, Mendenhall, C. Flowers, 2016 .

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2008 .

Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

A. Zelenetz, S. Horwitz, A. Intlekofer, 2016 .

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

L. Staudt, W. Wilson, L. Sehn, 2018, Blood.

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

I. Flinn, S. Horwitz, A. Younes, 2012 .

A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

L. Staudt, W. Wilson, R. Gascoyne, 2014 .

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.

S. Kondo, G. Georgakis, A. Younes, 2008, Experimental hematology.

Role of PET/CT Versus Conventional Ct in Post-Operative Follow up of Breast Cancer Patients

A. Younes, O. Omar, H. Khater, 2020 .

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

V. Seshan, A. Zelenetz, E. Papaemmanuil, 2018, Blood Cancer Journal.

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

L. Vassilev, M. Konopleva, M. Andreeff, 2011 .

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

I. Lossos, V. Seshan, A. Zelenetz, 2020 .

Nuclear Transcription Factor-kappaB in Hodgkin's Disease

B. Aggarwal, A. Younes, A. Garg, 2003, Leukemia & lymphoma.

Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant.

A. Younes, V. Ribrag, S. Hirawat, 2009 .

Thalidomide for patients with recurrent lymphoma

P. Mclaughlin, F. Cabanillas, M. Albitar, 2004, Cancer.

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

K. Savage, M. Shipp, A. Santoro, 2016 .

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin’s lymphoma

Juan F. García, A. M. Martín-Moreno, M. Piris, 2012, Haematologica.

Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.

Emily R. Levy, C. Ziegler, M. V. D. van den Brink, 2016, Cancer research.

Improvements in Treatments for Hodgkin Lymphoma Over a 50-Year Period Lead to Fewer Second Malignancies

Christine F. Wogan, S. Shirvani, Y. Oki, 2014 .

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.

S. Horwitz, A. Younes, P. Porcu, 2018, Blood advances.

Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

D. Podoloff, P. Mclaughlin, N. Ueno, 2006 .

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

A. Zelenetz, A. Younes, H. Schöder, 2018 .

Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

FOLLOW-UP OF HODGKIN LYMPHOMA Expert

L. Constine, A. Younes, Christopher R. Flowers, 2014 .

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

A. Younes, N. Dang, B. Pro, 2004 .

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

S. Faria, Y. Oki, L. Medeiros, 2012, Leukemia & lymphoma.

The lymphomas: molecular pathways and novel therapeutic targets.

A. Younes, B. Pro, A. Wedgwood, 2005, Current hematology reports.

Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Annals of Oncology.

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2000, Seminars in oncology.

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

H. Kantarjian, F. Cabanillas, A. Younes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.

K. Young, A. Younes, E. Sotomayor, 2014, Clinical advances in hematology & oncology : H&O.

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

R. Advani, A. Zelenetz, J. Friedberg, 2022, Blood.

Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.

G. Garcia-Manero, A. Younes, R. Martell, 2009 .

The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma.

A. Younes, D. Buglio, V. Mamidipudi, 2009 .

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

W. Wilson, V. Seshan, R. Advani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta.

I. Orlow, R. Kolesnick, A. Younes, 1993, Science.

EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS

J. Vose, J. Fitzgibbon, N. Nagy, 2019, Hematological Oncology.

Multiple myeloma and the road to personalised medicine.

A. Hagenbeek, S. Rajkumar, S. Russell, 2011, The Lancet. Oncology.

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma

V. Seshan, G. Salles, A. Younes, 2022, Blood Advances.

Phase II study of oxaliplatin in patients with recurrent or refractory non‐Hodgkin lymphoma

A. Bleyer, Y. Oki, P. Mclaughlin, 2005, Cancer.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

P. Mclaughlin, J. Cox, F. Cabanillas, 1998, Blood.

Favorable Stage I and

Mendenhall, L. Constine, A. Younes, 2016 .

The new therapeutical scenario of Hodgkin lymphoma.

A. Stathis, A. Younes, A. Younes, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

A. Zelenetz, S. Horwitz, A. Younes, 2023, Haematologica.

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

H. Tun, A. Younes, R. Martell, 2019, Blood.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

A. Zelenetz, A. Dogan, A. Younes, 2023, Haematologica.

CD40 ligand therapy of lymphoma patients.

J. Gribben, A. Younes, J. Dutcher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

XIV. The rationale for combining targeted and biological anti‐lymphoma drugs

A. Younes, 2013, Hematological Oncology.

A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study.

R. Advani, A. Younes, J. Drachman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated serum BLyS levels in patients with non-Hodgkin lymphoma

Y. Oki, G. Georgakis, A. Younes, 2007, Leukemia & lymphoma.

Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma

Y. Oki, G. Georgakis, A. Younes, 2007 .

Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.

Y. Oki, G. Georgakis, A. Younes, 2007, Haematologica.

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

S. Faria, J. Wood, P. Mclaughlin, 2009 .

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

V. Seshan, A. Zelenetz, A. Dogan, 2023, Leukemia and Lymphoma.

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

P. Mclaughlin, A. Younes, L. Kwak, 2005 .

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

A. Younes, R. Booher, M. Lunning, 2018, Blood.

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

I. Lossos, J. Burke, B. Cheson, 2019, Blood.

Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients (pts) with r/r non-Hodgkin lymphoma.

H. Tun, A. Younes, R. Martell, 2019, Journal of Clinical Oncology.

Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia.

A. Younes, M. Younes, M. Chirala, 2003, European journal of cancer.

Phase II study of idelalisib, a selective inhibitor of PI3K&dgr;, for relapsed/refractory classical Hodgkin lymphoma

A. Younes, S. Mitra, M. Fanale, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

P. Mclaughlin, A. Younes, L. Fayad, 2009 .

Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma

N. Socci, N. Schultz, V. Seshan, 2015 .

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

A. Younes, Nousheen Samad, 2010 .

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, D. Podoloff, 2006 .

In vitro and in vivo biologic effects of interleukin-3 (IL-3) in follicular low-grade lymphoma.

A. Younes, R. J. Shade, 1997, Leukemia & lymphoma.

The clinical significance of molecular response in indolent follicular lymphomas.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1998, Blood.

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

M. Dyer, A. Freedman, D. Heo, 2014, British journal of haematology.

Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.

A. Younes, A. Abu-Alfa, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Endothelial progenitor cells in non-Hodgkin's lymphoma.

Y. Oki, A. Younes, 2007, Haematologica.

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

W. Hiddemann, R. Marcus, C. Ward, 2020 .

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E. Smith, J. Connors, S. de Vos, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

A. Younes, R. Bugarini, D. Ritchie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Michael L. Wang, Y. Oki, A. Younes, 2014, British journal of haematology.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2013, British journal of haematology.

Utility of mTOR inhibition in hematologic malignancies.

A. Younes, Nousheen Samad, 2011, The oncologist.

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Current and emerging new treatment strategies for mantle cell lymphoma

A. Younes, K. Humala, 2013, Leukemia & lymphoma.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael L. Wang, A. Younes, J. Zeldis, 2008 .

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

P. Mclaughlin, A. Younes, L. Kwak, 2010 .

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2006 .

Positron-emission tomography e based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

V. Seshan, A. Zelenetz, M. Federico, 2020 .

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Y. Oki, Jiexin Zhang, Shouhao Zhou, 2013, Clinical Cancer Research.

Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma

B. Leber, P. Mclaughlin, A. Younes, 2005 .

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

P. Mclaughlin, A. Younes, L. Fayad, 2007 .

ACR Appropriateness Criteria s Hodgkin Lymphoma—Unfavorable Clinical Stage I and II

R. Advani, L. Constine, A. Younes, 2016 .

The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism

A. Younes, D. Buglio, R. Martell, 2010, British journal of haematology.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2009 .

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

V. Seshan, J. Baselga, D. Scheinberg, 2018, JCI insight.

Paclitaxel-based treatment of lymphoma.

A. Younes, 1999, Seminars in oncology.

High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

A. Younes, A. Rosenthal, 2017, Blood reviews.

ACR Appropriateness Criteria: Localized nodal indolent lymphoma.

R. Advani, C. Flowers, L. Constine, 2013, Oncology.

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

P. Mclaughlin, F. Cabanillas, M. Overman, 2007 .

Phase 1 Study of CA-4948, a Novel Inhibitor of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in Patients with R/R Non-Hodgkin Lymphoma (NHL)

H. Tun, A. Younes, R. Martell, 2019, Clinical Lymphoma Myeloma and Leukemia.

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

I. Flinn, P. Trojer, M. Maris, 2022, Cancer research communications.

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.

D. Scheinberg, T. Gardner, A. Younes, 2023, Blood.